PET/MR in Locally Advanced Nasopharyngeal Carcinoma
PET/MR in Locally Advanced Nasopharyngeal Carcinoma
ClinicalTrials.gov ID
NCT03657017
Lead Sponsor
Zhejiang Cancer HospitalOTHER
Overall Status
Unknown status
Study Type
Interventional
Phase
Not Applicable
Enrollment
150Estimated
Last Update Posted
Sep 4, 2018Actual
Start Date
Jun 1, 2018Actual
Primary Completion Date
Jun 1, 2022Estimated
Completion Date
Dec 30, 2025Estimated
Official Title
PET/MR in Locally Advanced Nasopharyngeal Carcinoma
Brief Summary
PET/MR in Locally Advanced Nasopharyngeal Carcinoma
Nasopharyngeal Carcinoma
PET/MR
PET/MR
Ages Eligible for Study
Child (0-17)Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients with newly histologically confirmed non-keratinizing carcinoma.
Tumor staged T1-4N0-3M0 （according to the 8th AJCC staging system）
Performance status: KPS>70
With normal liver function test (ALT, AST <1.5ULN)
Renal: creatinine clearance >60ml/min
Without hematopathy,marrow: WBC >4*109/L, HGB>80G/L, and PLT>100*109/L.
Written informed consent
Exclusion Criteria:
Adenocarcinoma
Age >70
Prior malignancy (except adequately treated carcinoma in-situ of the cervix or · basal/squamous cell carcinoma of the skin)
Previous chemotherapy or radiotherapy (except non-melanomatous skin cancers outside the intended RT treatment volume)
Patient is pregnant or lactating
Any severe intercurrent disease, which may bring unacceptable risk or affect the compliance of the trial, for example, unstable cardiac disease requiring treatment, renal disease, chronic hepatitis, diabetes with poor control (fasting plasma glucose >1.5×ULN), or emotional disturbance.